QuidelOrthoQDEL
QDEL
About: QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
Employees: 7,100
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
123% more call options, than puts
Call options by funds: $15M | Put options by funds: $6.71M
43% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 69
42% more capital invested
Capital invested by funds: $2.32B [Q2] → $3.3B (+$980M) [Q3]
29% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 9 (+2) [Q3]
3.35% more ownership
Funds ownership: 104.49% [Q2] → 107.84% (+3.35%) [Q3]
2% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 54
1% less funds holding
Funds holding: 260 [Q2] → 258 (-2) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$43
3%
upside
Avg. target
$47
11%
upside
High target
$50
20%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Citigroup Patrick Donnelly 47% 1-year accuracy 15 / 32 met price target | 20%upside $50 | Buy Upgraded | 11 Dec 2024 |
Jefferies Tycho Peterson 42% 1-year accuracy 5 / 12 met price target | 3%upside $43 | Hold Initiated | 10 Dec 2024 |
Financial journalist opinion
Based on 4 articles about QDEL published over the past 30 days
Negative
Zacks Investment Research
6 days ago
QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues
QDEL's preliminary fourth-quarter revenues align with the company's expectations.
Neutral
Business Wire
1 week ago
QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately.
Neutral
PRNewsWire
1 week ago
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory.
Neutral
Business Wire
2 weeks ago
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Company's presentation is scheduled for Monday, January 13, 2025 at 7:30 a.m. PST / 10:30 a.m. EST. Interested parties can access the live webcast.
Neutral
Business Wire
1 month ago
QuidelOrtho Announces Appointment of Two Independent Directors to its Board
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the “Board”), effective December 6, 2024. These appointments align with QuidelOrtho's commitment to maintaining a strong, independent Board with the ri.
Neutral
Zacks Investment Research
1 month ago
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
Positive
Benzinga
2 months ago
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
On Tuesday, QuidelOrtho Corporation QDEL priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.
Negative
Benzinga
2 months ago
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Neutral
Business Wire
2 months ago
QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selli.
Neutral
Business Wire
2 months ago
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selling Stockholder will rec.
Charts implemented using Lightweight Charts™